These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 24966601)
1. Does antiviral therapy reduce complications of cirrhosis? Chung GE; Lee JH; Kim YJ World J Gastroenterol; 2014 Jun; 20(23):7306-11. PubMed ID: 24966601 [TBL] [Abstract][Full Text] [Related]
2. Is HBV viral load at admission associated with development of acute-on-chronic liver failure in patients with acute decompensation of chronic hepatitis B related cirrhosis? Lei JH; Peng F; Chen Z; Xiao XQ BMC Infect Dis; 2019 Apr; 19(1):363. PubMed ID: 31039732 [TBL] [Abstract][Full Text] [Related]
3. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Brown A; Goodman Z Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):187-98. PubMed ID: 22375524 [TBL] [Abstract][Full Text] [Related]
4. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121 [TBL] [Abstract][Full Text] [Related]
5. Treatment of HBV-related cirrhosis. Vallet-Pichard A; Mallet V; Costentin CE; Pol S Expert Rev Anti Infect Ther; 2009 Jun; 7(5):527-35. PubMed ID: 19485793 [TBL] [Abstract][Full Text] [Related]
6. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Okada M; Enomoto M; Kawada N; Nguyen MH Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768 [TBL] [Abstract][Full Text] [Related]
7. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. Seo Y; Yano Y World J Gastroenterol; 2014 Oct; 20(37):13284-92. PubMed ID: 25309065 [TBL] [Abstract][Full Text] [Related]
8. Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study. Gu EL; Yu YQ; Wang JL; Ji YY; Ma XY; Xie Q; Pan HY; Wu SM; Li J; Chen CW; Xu XW; Wang YE; Yao GB; Wang H; Zhang WH World J Gastroenterol; 2015 Jan; 21(2):653-60. PubMed ID: 25605989 [TBL] [Abstract][Full Text] [Related]
9. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B. Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267 [TBL] [Abstract][Full Text] [Related]
10. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649 [TBL] [Abstract][Full Text] [Related]
11. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387 [TBL] [Abstract][Full Text] [Related]
12. The impact of HBV flare on the outcome of HBV-related decompensated cirrhosis patients with bacterial infection. Cao Z; Liu Y; Wang S; Lu X; Yin S; Jiang S; Chen L; Cai M; Zeng B; Yao Y; Tang W; Zhao G; Xiang X; Wang H; Cai W; Zhu C; Li H; Xie Q Liver Int; 2019 Oct; 39(10):1943-1953. PubMed ID: 31206235 [TBL] [Abstract][Full Text] [Related]
13. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis]. Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949 [TBL] [Abstract][Full Text] [Related]
14. Management of chronic hepatitis B in severe liver disease. Fung J; Lai CL; Yuen MF World J Gastroenterol; 2014 Nov; 20(43):16053-61. PubMed ID: 25473157 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Liaw YF Antivir Ther; 2006; 11(6):669-79. PubMed ID: 17310811 [TBL] [Abstract][Full Text] [Related]
16. Prevention of hepatocellular carcinoma in hepatitis B virus infection. Lim SG; Mohammed R; Yuen MF; Kao JH J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903 [TBL] [Abstract][Full Text] [Related]
18. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. Tseng PL; Lu SN; Tung HD; Wang JH; Changchien CS; Lee CM J Viral Hepat; 2005 Jul; 12(4):386-92. PubMed ID: 15985009 [TBL] [Abstract][Full Text] [Related]
19. Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Zhang Y; Hu XY; Zhong S; Yang F; Zhou TY; Chen G; Wang YY; Luo JX World J Gastroenterol; 2014 Apr; 20(16):4745-52. PubMed ID: 24782628 [TBL] [Abstract][Full Text] [Related]
20. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. Lian JS; Zeng LY; Chen JY; Jia HY; Zhang YM; Xiang DR; Yu L; Hu JH; Lu YF; Zheng L; Li LJ; Yang YD World J Gastroenterol; 2013 Oct; 19(37):6278-83. PubMed ID: 24115827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]